Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
20 participants
INTERVENTIONAL
2000-06-30
2004-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
NCT00692185
Olanzapine in the Treatment of Patients With Anorexia Nervosa
NCT00260962
Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa
NCT00685334
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
NCT00051298
Olanzapine Treatment of Patients With Bipolar I Disorder
NCT00510146
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
olanzapine
olanzapine
flexibly dosed oral olanzapine 2.5 to 15 mg/day
2
matching placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
olanzapine
flexibly dosed oral olanzapine 2.5 to 15 mg/day
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
12 Years
23 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Northwell Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
North Shore- Long Island Jewish Health System
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vivian Kafantaris, M.D.
Role: PRINCIPAL_INVESTIGATOR
Schneider Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Schneider Children's Hospital
New Hyde Park, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, Saito E, Sunday S, Higdon C, Golden NH, Malhotra AK. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011 Jun;21(3):207-12. doi: 10.1089/cap.2010.0139.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Lilly F1D-US-X166
Identifier Type: -
Identifier Source: secondary_id
99-04-072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.